Enhanced antigen presentation, T‐cell activation, inhibition of CCR4/CCL22 axis to suppress Tregs, increased therapeutic efficacy in pancreatic ductal adenocarcinoma (PDAC) when combined with chemotherapy. Here, CCL22 is linked to pancreatic ductal adenocarcinoma.